Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

David Erlinge, Stefan James, Suman Duvvuru, Joseph A. Jakubowski, Henrik Wagner, Christoph Varenhorst, Udaya S. Tantry, Patricia B. Brown, David Small, Brian A. Moser, Scott S. Sundseth, Joseph R. Walker, Kenneth J. Winters, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

We compared results obtained with the Nanosphere Verigene® System, a novel point-of-care (POC) genetic test capable of analysing 11 CYP2C19 variants within 3 hours, to an established, validated genotyping method (Affymetrix™ DMET+; reference assay) for identifying extensive and reduced metabolisers of clopidogrel. Based on genotyping, patients (N=82) with stable coronary artery disease on clopidogrel 75 mg daily were defined as extensive metabolisers (*1/*1, *1/*17, *17/*17), reduced metabolisers (*1/*2, *1/*8, *2/*2, *2/*3), or of indeterminate metaboliser status (*2/*17). Pharmacokinetic exposure to clopidogrel's active metabolite and pharmacodynamic measures with P2Y12 reaction units (PRU) (VerifyNow® P2Y12 assay) and VASP PRI (PRI) were also assessed. There was a 99.9% overall concordance of marker-level data between the Nanosphere Verigene and DMET+ systems in identifying the CYP2C19 variants and 100% agreement in classifying the patients as extensive (n=59) or reduced metabolisers (n=15). Extensive metabolisers had significantly higher active metabolite exposure than reduced metabolisers (LS means 12.6 ng*h/ml vs 7.7 ng*h/ml; p235: 33% vs 16%). The Nanosphere Verigene CBS system identified 11 CYP2C19 alleles in less than 3 hours with a high degree of accuracy when compared to a conventional method, and was further validated against pharmacokinetic and pharmacodynamic phenotypes.

Original languageEnglish (US)
Pages (from-to)943-950
Number of pages8
JournalThrombosis and Haemostasis
Volume111
Issue number5
DOIs
StatePublished - 2014

Fingerprint

clopidogrel
Point-of-Care Systems
Nanospheres
Genetic Testing
Coronary Artery Disease
Pharmacokinetics
Alleles
Phenotype
Cytochrome P-450 CYP2C19

Keywords

  • Clopidogrel
  • Genotyping techniques
  • Pharmacogenetics CYP2C19 polymorphisms
  • Prasugrel

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Erlinge, D., James, S., Duvvuru, S., Jakubowski, J. A., Wagner, H., Varenhorst, C., ... Gurbel, P. A. (2014). Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thrombosis and Haemostasis, 111(5), 943-950. https://doi.org/10.1160/TH13-09-0767

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. / Erlinge, David; James, Stefan; Duvvuru, Suman; Jakubowski, Joseph A.; Wagner, Henrik; Varenhorst, Christoph; Tantry, Udaya S.; Brown, Patricia B.; Small, David; Moser, Brian A.; Sundseth, Scott S.; Walker, Joseph R.; Winters, Kenneth J.; Gurbel, Paul A.

In: Thrombosis and Haemostasis, Vol. 111, No. 5, 2014, p. 943-950.

Research output: Contribution to journalArticle

Erlinge, D, James, S, Duvvuru, S, Jakubowski, JA, Wagner, H, Varenhorst, C, Tantry, US, Brown, PB, Small, D, Moser, BA, Sundseth, SS, Walker, JR, Winters, KJ & Gurbel, PA 2014, 'Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease', Thrombosis and Haemostasis, vol. 111, no. 5, pp. 943-950. https://doi.org/10.1160/TH13-09-0767
Erlinge, David ; James, Stefan ; Duvvuru, Suman ; Jakubowski, Joseph A. ; Wagner, Henrik ; Varenhorst, Christoph ; Tantry, Udaya S. ; Brown, Patricia B. ; Small, David ; Moser, Brian A. ; Sundseth, Scott S. ; Walker, Joseph R. ; Winters, Kenneth J. ; Gurbel, Paul A. / Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. In: Thrombosis and Haemostasis. 2014 ; Vol. 111, No. 5. pp. 943-950.
@article{6e7aa7189352469783dfb1198799b7a5,
title = "Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease",
abstract = "We compared results obtained with the Nanosphere Verigene{\circledR} System, a novel point-of-care (POC) genetic test capable of analysing 11 CYP2C19 variants within 3 hours, to an established, validated genotyping method (Affymetrix™ DMET+; reference assay) for identifying extensive and reduced metabolisers of clopidogrel. Based on genotyping, patients (N=82) with stable coronary artery disease on clopidogrel 75 mg daily were defined as extensive metabolisers (*1/*1, *1/*17, *17/*17), reduced metabolisers (*1/*2, *1/*8, *2/*2, *2/*3), or of indeterminate metaboliser status (*2/*17). Pharmacokinetic exposure to clopidogrel's active metabolite and pharmacodynamic measures with P2Y12 reaction units (PRU) (VerifyNow{\circledR} P2Y12 assay) and VASP PRI (PRI) were also assessed. There was a 99.9{\%} overall concordance of marker-level data between the Nanosphere Verigene and DMET+ systems in identifying the CYP2C19 variants and 100{\%} agreement in classifying the patients as extensive (n=59) or reduced metabolisers (n=15). Extensive metabolisers had significantly higher active metabolite exposure than reduced metabolisers (LS means 12.6 ng*h/ml vs 7.7 ng*h/ml; p235: 33{\%} vs 16{\%}). The Nanosphere Verigene CBS system identified 11 CYP2C19 alleles in less than 3 hours with a high degree of accuracy when compared to a conventional method, and was further validated against pharmacokinetic and pharmacodynamic phenotypes.",
keywords = "Clopidogrel, Genotyping techniques, Pharmacogenetics CYP2C19 polymorphisms, Prasugrel",
author = "David Erlinge and Stefan James and Suman Duvvuru and Jakubowski, {Joseph A.} and Henrik Wagner and Christoph Varenhorst and Tantry, {Udaya S.} and Brown, {Patricia B.} and David Small and Moser, {Brian A.} and Sundseth, {Scott S.} and Walker, {Joseph R.} and Winters, {Kenneth J.} and Gurbel, {Paul A.}",
year = "2014",
doi = "10.1160/TH13-09-0767",
language = "English (US)",
volume = "111",
pages = "943--950",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "5",

}

TY - JOUR

T1 - Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

AU - Erlinge, David

AU - James, Stefan

AU - Duvvuru, Suman

AU - Jakubowski, Joseph A.

AU - Wagner, Henrik

AU - Varenhorst, Christoph

AU - Tantry, Udaya S.

AU - Brown, Patricia B.

AU - Small, David

AU - Moser, Brian A.

AU - Sundseth, Scott S.

AU - Walker, Joseph R.

AU - Winters, Kenneth J.

AU - Gurbel, Paul A.

PY - 2014

Y1 - 2014

N2 - We compared results obtained with the Nanosphere Verigene® System, a novel point-of-care (POC) genetic test capable of analysing 11 CYP2C19 variants within 3 hours, to an established, validated genotyping method (Affymetrix™ DMET+; reference assay) for identifying extensive and reduced metabolisers of clopidogrel. Based on genotyping, patients (N=82) with stable coronary artery disease on clopidogrel 75 mg daily were defined as extensive metabolisers (*1/*1, *1/*17, *17/*17), reduced metabolisers (*1/*2, *1/*8, *2/*2, *2/*3), or of indeterminate metaboliser status (*2/*17). Pharmacokinetic exposure to clopidogrel's active metabolite and pharmacodynamic measures with P2Y12 reaction units (PRU) (VerifyNow® P2Y12 assay) and VASP PRI (PRI) were also assessed. There was a 99.9% overall concordance of marker-level data between the Nanosphere Verigene and DMET+ systems in identifying the CYP2C19 variants and 100% agreement in classifying the patients as extensive (n=59) or reduced metabolisers (n=15). Extensive metabolisers had significantly higher active metabolite exposure than reduced metabolisers (LS means 12.6 ng*h/ml vs 7.7 ng*h/ml; p235: 33% vs 16%). The Nanosphere Verigene CBS system identified 11 CYP2C19 alleles in less than 3 hours with a high degree of accuracy when compared to a conventional method, and was further validated against pharmacokinetic and pharmacodynamic phenotypes.

AB - We compared results obtained with the Nanosphere Verigene® System, a novel point-of-care (POC) genetic test capable of analysing 11 CYP2C19 variants within 3 hours, to an established, validated genotyping method (Affymetrix™ DMET+; reference assay) for identifying extensive and reduced metabolisers of clopidogrel. Based on genotyping, patients (N=82) with stable coronary artery disease on clopidogrel 75 mg daily were defined as extensive metabolisers (*1/*1, *1/*17, *17/*17), reduced metabolisers (*1/*2, *1/*8, *2/*2, *2/*3), or of indeterminate metaboliser status (*2/*17). Pharmacokinetic exposure to clopidogrel's active metabolite and pharmacodynamic measures with P2Y12 reaction units (PRU) (VerifyNow® P2Y12 assay) and VASP PRI (PRI) were also assessed. There was a 99.9% overall concordance of marker-level data between the Nanosphere Verigene and DMET+ systems in identifying the CYP2C19 variants and 100% agreement in classifying the patients as extensive (n=59) or reduced metabolisers (n=15). Extensive metabolisers had significantly higher active metabolite exposure than reduced metabolisers (LS means 12.6 ng*h/ml vs 7.7 ng*h/ml; p235: 33% vs 16%). The Nanosphere Verigene CBS system identified 11 CYP2C19 alleles in less than 3 hours with a high degree of accuracy when compared to a conventional method, and was further validated against pharmacokinetic and pharmacodynamic phenotypes.

KW - Clopidogrel

KW - Genotyping techniques

KW - Pharmacogenetics CYP2C19 polymorphisms

KW - Prasugrel

UR - http://www.scopus.com/inward/record.url?scp=84899706203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899706203&partnerID=8YFLogxK

U2 - 10.1160/TH13-09-0767

DO - 10.1160/TH13-09-0767

M3 - Article

C2 - 24402637

AN - SCOPUS:84899706203

VL - 111

SP - 943

EP - 950

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -